Immune-modified ex vivo platform can measure treatment response of ovarian cancer

[News]

KIYATEC, Inc researchers demonstrated that their immune-modified ex vivo platform can measure treatment response through direct interaction between a patient's cancer and infiltrating immune cells, and immuno-oncology agents.

More... (https://www.news-medical.net/news/20210312/Immune-modified-ex-vivo-platform-can-measure-treatment-response-of-ovarian-cancer.aspx)